Dataset Information

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

ABSTRACT: Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

PROVIDER: PRJNA1078705 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	SRR28026800_1.fastq.gz	Fastqsanger.gz
	SRR28026800_2.fastq.gz	Fastqsanger.gz
	SRR28026801_1.fastq.gz	Fastqsanger.gz
	SRR28026801_2.fastq.gz	Fastqsanger.gz
	SRR28026802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Project description:Enhancer of Zeste Homolog 2 (EZH2) and androgen receptor (AR) are both crucial for the development and progression of prostate tumor, including advanced castration-resistant prostate cancer (CRPC). Previously, it was reported that, in order to sustain tumorigenicity of prostate cancer, EZH2 has noncanonical functions in interaction with AR for mediating gene activation, in addition to its canonical role as a transcriptional repressor and enzymatic subunit of Polycomb Repressive Complex 2 (PRC2). However, the molecular basis underlying non-canonical activities of EZH2 in prostate cancer remains far from clear, and therapeutic strategies for targeting EZH2:AR-mediated gene-activation activities are also lacking. Here, we report that a hidden transactivation domain of EZH2 (EZH2TAD) binds both AR and AR’s variants enriched in CRPCs, notably AR splice variant 7 (AR-V7), mediating the assembly and/or recruitment of a gene-activation-related complex at genomic sites that lack PRC2 binding. Such noncanonical targets of EZH2:AR/AR-V7:(co)activators are enriched for the clinically-relevant prostate oncogenes. EZH2TAD is crucial for EZH2-mediated transactivation of oncogenes and for CRPC growth in vitro and in vivo. To completely block EZH2’s multifaceted oncogenic activities in prostate cancer, we employed MS177, a recently developed proteolysis targeting chimera (PROTAC) of EZH2. MS177 achieved on-target depletion of both EZH2’s canonical (EZH2:PRC2) and noncanonical (EZH2TAD:AR/AR-V7:coactivators) complexes in prostate tumor, eliciting much more potent antitumor effects than the existing catalytic inhibitors of EZH2. Overall, this study reports previously unappreciated requirements of EZH2TAD for mediating EZH2’s noncanonical recruitment and gene-activation functions in prostate tumor and suggests EZH2-targeting PROTACs as potentially attractive therapeutics for the treatment of aggressive prostate tumors that reply on circuits wired by EZH2 and AR.

Dataset Information

Epigenetic profiling of prostate adenocarcinoma and neuroendocrine prostate cancer models to understand EZH2 activity. [Cut & Run]

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets